Overview
International law firm McDermott Will & Emery represented Intensity Therapeutics, Inc., a clinical-stage biotechnology company focused on the discovery and development of proprietary, novel immune-based intratumoral cancer therapies designed to kill tumors and increase immune system recognition of cancers, in its $22.4 million initial public offering (IPO) of 4,485,000 shares of its common stock at a price of $5.00 per share (which includes 585,000 shares issued pursuant to the exercise in full of the underwriter’s over-allotment option).
The common stock began trading on the Nasdaq Capital Market under the symbol “INTS” on June 30, 2023. The base offering closed on July 5, 2023 and the issuance of the underwriters’ over-allotment shares occurred on July 7, 2023.
The McDermott deal team was led by Robert Cohen and Dan Woodard and included Evan Belosa, Brandon Sloane, Allison Perlman and Michael Blane.
Read Intensity Therapeutics, Inc.’s press release here.
About McDermott
McDermott Will & Emery partners with leaders around the world to fuel missions, knock down barriers and shape markets. Our team works seamlessly across practices and industries to deliver highly effective solutions that propel success. More than 1,400 lawyers strong, we bring our personal passion and legal prowess to bear in every matter for our clients and the people they serve.
